MedTrace Logo

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

NCT04037891 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-04-10

Study results available
· View outcomes & findings →

Summary

Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel trial (TRACKER)

Conditions

  • Keratoconjunctivitis, Atopic
  • Keratoconjunctivitis, Vernal
  • Conjunctivitis, Allergic

Interventions

DRUG

rVA576

Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.

OTHER

Placebo

Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.

DRUG

rVA576

Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.

Sponsors & Collaborators

  • AKARI Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sajjad Ahmad · Moorfields Eye Hospital NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04037891 on ClinicalTrials.gov